Department of Orthopaedics and Sports Medicine, The University of Washington, Seattle, WA 98195, USA.
Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:107-11. doi: 10.1002/dmrr.2245.
Most estimates in the literature for the economic cost of treating a diabetic foot ulcer (DFU) are from industrialized countries. There is also marked heterogeneity between the complexity of cases considered in the different studies. The goal of the present article was to estimate treatment costs and costs to patients in five different countries (Chile, China, India, Tanzania, and the United States) for two hypothetical, but well-defined, DFUs at the extreme ends of the complexity spectrum. A co-author, who is a treating physician in the relevant country, was asked to choose treatment plans that represented the typical application of local resources to the DFU. The outcomes were pre-defined as complete healing in case 1 and trans-tibial amputation in case 2, but the time course of treatment was determined by each investigator in a manner that would be typical for their clinic. The costs, in local currencies, for each course of treatment were estimated with the assistance of local hospital administrators. Typical reimbursement scenarios in each country were used to estimate the cost burden to the patient, which was then expressed as a percentage of the annual per capita purchasing power parity-adjusted gross domestic product. There were marked differences in the treatment plans between countries based on the availability of resources and the realities of local conditions. The costs of treatment for case 1 ranged from Int$102 to Int$3959 in Tanzania and in the United States, respectively. The cost for case 2 ranged from Int$3060 to Int$188,645 in Tanzania and in the United States, respectively. The cost burden to the patient varied from the equivalent of 6 days of average income in the United States for case 1 to 5.7 years of average annual income for case 2 in India. Although these findings do not take cost-effectiveness into account, they highlight the dramatic economic burden of a DFU for patients in some countries.
大多数文献中对治疗糖尿病足溃疡(DFU)的经济成本的估计都来自工业化国家。不同研究中考虑的病例复杂性也存在明显差异。本文的目的是估计五个不同国家(智利、中国、印度、坦桑尼亚和美国)两种假设的、但定义明确的 DFU 的治疗成本和患者成本,这两种 DFU 处于复杂性谱的两个极端。一位协作者是相关国家的治疗医生,被要求选择代表当地资源对 DFU 的典型应用的治疗方案。结果被预先定义为病例 1 完全愈合和病例 2 经胫骨截肢,但每个研究者根据他们诊所的典型情况确定治疗过程的时间。在当地医院管理人员的协助下,用当地货币估计每种治疗方案的成本。使用每个国家的典型报销方案来估计患者的成本负担,然后将其表示为人均购买力平价调整后的国内生产总值的年度百分比。基于资源的可用性和当地实际情况,各国之间的治疗方案存在明显差异。病例 1 的治疗费用在坦桑尼亚和美国分别为 102 至 3959 国际元。病例 2 的治疗费用在坦桑尼亚和美国分别为 3060 至 188645 国际元。病例 1 对患者的成本负担相当于美国的 6 天平均收入,而病例 2 在印度相当于 5.7 年的平均年收入。尽管这些发现没有考虑成本效益,但它们突出了 DFU 对一些国家患者的巨大经济负担。